AU2013329451B2 - Potassium-binding agents for treating hypertension and hyperkalemia - Google Patents

Potassium-binding agents for treating hypertension and hyperkalemia Download PDF

Info

Publication number
AU2013329451B2
AU2013329451B2 AU2013329451A AU2013329451A AU2013329451B2 AU 2013329451 B2 AU2013329451 B2 AU 2013329451B2 AU 2013329451 A AU2013329451 A AU 2013329451A AU 2013329451 A AU2013329451 A AU 2013329451A AU 2013329451 B2 AU2013329451 B2 AU 2013329451B2
Authority
AU
Australia
Prior art keywords
patient
potassium
binding agent
egfr
acr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013329451A
Other languages
English (en)
Other versions
AU2013329451A1 (en
Inventor
Lance Berman
Gerrit Klaerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013329451(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of AU2013329451A1 publication Critical patent/AU2013329451A1/en
Application granted granted Critical
Publication of AU2013329451B2 publication Critical patent/AU2013329451B2/en
Priority to AU2018260862A priority Critical patent/AU2018260862B2/en
Assigned to Vifor Pharma Technology Ltd. reassignment Vifor Pharma Technology Ltd. Request for Assignment Assignors: RELYPSA, INC.
Priority to AU2020294307A priority patent/AU2020294307B2/en
Assigned to VIFOR (INTERNATIONAL) LTD. reassignment VIFOR (INTERNATIONAL) LTD. Request to Amend Deed and Register Assignors: Vifor Pharma Technology Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AU2013329451A 2012-10-08 2013-10-08 Potassium-binding agents for treating hypertension and hyperkalemia Active AU2013329451B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018260862A AU2018260862B2 (en) 2012-10-08 2018-11-07 Potassium-binding agents for treating hypertension and hyperkalemia
AU2020294307A AU2020294307B2 (en) 2012-10-08 2020-12-24 Potassium-binding agents for treating hypertension and hyperkalemia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711184P 2012-10-08 2012-10-08
US61/711,184 2012-10-08
PCT/US2013/063921 WO2014058905A2 (en) 2012-10-08 2013-10-08 Potassium-binding agents for treating hypertension and hyperkalemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018260862A Division AU2018260862B2 (en) 2012-10-08 2018-11-07 Potassium-binding agents for treating hypertension and hyperkalemia

Publications (2)

Publication Number Publication Date
AU2013329451A1 AU2013329451A1 (en) 2015-04-23
AU2013329451B2 true AU2013329451B2 (en) 2018-08-09

Family

ID=49385427

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013329451A Active AU2013329451B2 (en) 2012-10-08 2013-10-08 Potassium-binding agents for treating hypertension and hyperkalemia
AU2018260862A Active AU2018260862B2 (en) 2012-10-08 2018-11-07 Potassium-binding agents for treating hypertension and hyperkalemia
AU2020294307A Active AU2020294307B2 (en) 2012-10-08 2020-12-24 Potassium-binding agents for treating hypertension and hyperkalemia

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018260862A Active AU2018260862B2 (en) 2012-10-08 2018-11-07 Potassium-binding agents for treating hypertension and hyperkalemia
AU2020294307A Active AU2020294307B2 (en) 2012-10-08 2020-12-24 Potassium-binding agents for treating hypertension and hyperkalemia

Country Status (11)

Country Link
US (6) US10813946B2 (https=)
EP (2) EP4684832A3 (https=)
JP (4) JP6475624B2 (https=)
KR (2) KR20210005314A (https=)
CN (2) CN104822383A (https=)
AU (3) AU2013329451B2 (https=)
BR (1) BR112015007749A2 (https=)
CA (1) CA2886788C (https=)
ES (1) ES3059226T3 (https=)
HK (1) HK1210705A1 (https=)
WO (1) WO2014058905A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
JP6475624B2 (ja) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
ITUB20159278A1 (it) * 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
CN105622602A (zh) * 2016-01-30 2016-06-01 合肥华方医药科技有限公司 一种沙坦类小檗碱偶合物制备方法及其医药用途
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP7691997B2 (ja) * 2020-03-27 2025-06-12 ヴィフォー （インターナショナル） リミテッド メチル２－フルオロアクリレートの合成
CN111978590B (zh) * 2020-09-04 2021-02-12 四川大学 一种沸石-肝素模拟聚合物共混微球、其制备方法及其应用
KR102647158B1 (ko) 2021-03-24 2024-03-15 강원대학교산학협력단 신규한 페디오코커스 악시딜락티시 균주 및 상기 균주를 이용하여 발효시킨 대두 발효물의 다양한 용도
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155370A1 (en) * 2005-09-30 2009-06-18 Relypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
WO2010022382A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022383A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US20120213847A1 (en) * 2011-02-11 2012-08-23 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487958A (en) * 1892-12-13 Patrick mccann
US2340111A (en) 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (https=) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4191812A (en) 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
ES2070307T3 (es) 1990-07-04 1995-06-01 Marcin Krotkiewski Una preparacion para el tratamiento de la hipertension.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
JPH08500386A (ja) 1992-08-20 1996-01-16 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 架橋ポリマーアンモニウム塩
WO1994027619A1 (en) 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH09506342A (ja) 1993-11-25 1997-06-24 サルテルナテ・ベー・ブイ 一価カチオンに結合する粒子、並びにナトリウムおよび／またはカリウムイオンを捕捉して除去するための上記粒子の使用および方法
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
WO1997049387A1 (en) 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
KR100440544B1 (ko) 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
IL142911A0 (en) 1998-11-06 2002-04-21 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
AU1998200A (en) 1999-01-07 2000-07-24 Elan Corporation, Plc Multiparticulate oral dosage forms
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US6569910B1 (en) 1999-10-27 2003-05-27 Basf Aktiengesellschaft Ion exchange resins and methods of making the same
EP1249240A4 (en) 2000-01-14 2003-03-19 Otsuka Pharma Co Ltd INHIBITORS OF SODIUM ION ABSORPTION, AND PROPHYLACTIC OR THERAPEUTIC AGENTS AND FOOD PRODUCTS CONTAINING SAID INHIBITORS
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
AU2002232955A1 (en) 2000-11-20 2002-05-27 Dow Global Technologies Inc. In vivo use of water absorbent polymers
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
EP1434752A2 (de) 2001-10-01 2004-07-07 Basf Aktiengesellschaft Verfahren zur herstellung von alkylarylverbindungen und sulfonaten davon
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
JP5826445B2 (ja) 2003-02-25 2015-12-02 フィンフィーズ フィンランド オイ 擬似移動床システム及び方法
WO2005065291A2 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
BRPI0509331B8 (pt) 2004-03-30 2021-05-25 Ilypsa Inc uso de uma composição de ligação de sódio
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CA2624112A1 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US20070248564A1 (en) 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
CN101835500B (zh) 2007-08-29 2014-05-28 吸附剂治疗学公司 具有可变抗衡离子含量的吸收性聚合物组合物及其制备方法和用途
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
ES2670580T3 (es) 2010-03-20 2018-05-31 Relypsa, Inc. Procedimiento continuo para preparar partículas de polifluoroacrilato
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US8697132B2 (en) * 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
CA2824441A1 (en) 2011-01-10 2012-07-19 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation - binding polymers and calcium and/or magnesium cations, and uses thereof
WO2013003495A2 (en) 2011-06-27 2013-01-03 Relypsa, Inc. Fluorination of acrylate esters and derivatives
US9453092B2 (en) 2011-06-27 2016-09-27 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid
HK1203420A1 (en) 2012-07-19 2015-10-30 Vifor (International) Ltd. Compositions comprising crosslinked cation-binding polymers
JP6475624B2 (ja) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155370A1 (en) * 2005-09-30 2009-06-18 Relypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
WO2010022382A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022383A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US20120213847A1 (en) * 2011-02-11 2012-08-23 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUYSSE J M ET AL, "PEARL-HF: Prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016", FUTURE CARDIOLOGY, 2012, vol. 8(1), pages 17 - 28 *

Also Published As

Publication number Publication date
EP2916851B1 (en) 2025-12-17
EP4684832A2 (en) 2026-01-28
AU2013329451A1 (en) 2015-04-23
US20180193377A1 (en) 2018-07-12
JP7113871B2 (ja) 2022-08-05
HK1210705A1 (en) 2016-05-06
JP2021095421A (ja) 2021-06-24
JP2018048211A (ja) 2018-03-29
CN119405686A (zh) 2025-02-11
US9925212B2 (en) 2018-03-27
US20140105848A1 (en) 2014-04-17
AU2020294307A1 (en) 2021-02-18
US10813946B2 (en) 2020-10-27
CN104822383A (zh) 2015-08-05
WO2014058905A3 (en) 2014-10-30
JP6475624B2 (ja) 2019-02-27
US20150110886A1 (en) 2015-04-23
KR20210005314A (ko) 2021-01-13
AU2020294307B2 (en) 2022-06-02
BR112015007749A2 (pt) 2017-07-04
CA2886788C (en) 2022-04-19
US11123363B2 (en) 2021-09-21
JP6817185B2 (ja) 2021-01-20
US20170020916A1 (en) 2017-01-26
ES3059226T3 (en) 2026-03-19
US9492476B2 (en) 2016-11-15
AU2018260862A1 (en) 2018-12-06
KR20150088243A (ko) 2015-07-31
US20210046104A1 (en) 2021-02-18
JP2016500672A (ja) 2016-01-14
AU2018260862B2 (en) 2020-10-08
CA2886788A1 (en) 2014-04-17
WO2014058905A2 (en) 2014-04-17
US20210038636A1 (en) 2021-02-11
EP4684832A3 (en) 2026-04-01
EP2916851A2 (en) 2015-09-16
JP2020176155A (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
AU2020294307B2 (en) Potassium-binding agents for treating hypertension and hyperkalemia
DK2957286T3 (en) Compositions comprising cross-linked cation exchange polymers and use in the treatment of hyperkalaemia
WO2010022381A1 (en) Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010022380A2 (en) Linear polyol stabilized polyfluoroacrylate compositions
AU2013204879B2 (en) Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC1 Assignment before grant (sect. 113)

Owner name: VIFOR PHARMA TECHNOLOGY LTD.

Free format text: FORMER APPLICANT(S): RELYPSA, INC.

HB Alteration of name in register

Owner name: VIFOR (INTERNATIONAL) LTD.

Free format text: FORMER NAME(S): VIFOR PHARMA TECHNOLOGY LTD.